Summary

Eligibility
for people ages up to 30 years (full criteria)
Location
at Oakland, California and other locations
Dates
study started
completion around
Principal Investigator
by Jennifer G. MichlitschArun A. Rangaswami
Headshot of Jennifer G. Michlitsch
Jennifer G. Michlitsch
Headshot of Arun A. Rangaswami
Arun A. Rangaswami

Description

Summary

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).

Official Title

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Details

Keywords

Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor, Neoplasms, Wilms Tumor, Cyclophosphamide, Ifosfamide, Isophosphamide mustard, Carboplatin, Doxorubicin, Liposomal doxorubicin, Irinotecan, Etoposide, Vincristine, Etoposide phosphate, Daunorubicin, Topotecan, Podophyllotoxin, Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Surgical Procedure, Transabdominal Ultrasound, X-Ray Imaging

Eligibility

Locations

Lead Scientists at UCSF

  • Jennifer G. Michlitsch
    Professor, Pediatrics, School of Medicine. Authored (or co-authored) 23 research publications
  • Arun A. Rangaswami
    I am one of the senior solid tumor faculty at UCSF, having joined the institution in 2019. My scholarly and clinical practice have focused on the treatment of pediatric liver cancers and rare cancers.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Children's Oncology Group
ID
NCT04322318
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 221 study participants
Last Updated